Summary
The long-term efficacy of a new vasodilator, cadralazine (ISF 2469), and chlorthalidone have been compared in 20 hypertensive patients not adequately controlled by atenolol. After 4 weeks of treatment with atenolol 100 mg once daily, patients whose diastolic blood pressure was >95 mmHg were randomly divided into two groups to receive in addition to atenolol, either cadralazine 15 mg once daily or chlorthalidone 25 mg once daily. Both treatments were administered for 6 months. At the end of treatment with atenolol and after 3 and 6 months of combination therapy, blood pressure and heart rate were measured at rest and during bicycle exercise 24 h after the last dose. Compared to atenolol alone, both cadralazine and chlorthalidone caused a significant and similar reduction in resting blood pressure. Both groups showed an increase in diastolic blood pressure during exercise while receiving atenolol alone. The addition of chlorthalidone did not modify the pressor response to exercise, whereas patients taking cadralazine had a decrease in exercise diastolic blood pressure, which was fully evident after 6 months of therapy. The reduction in exercise diastolic blood pressure induced by cadralazine was proportional to the increase in exercise heart rate, suggesting a fall in peripheral vascular resistance. Chlorthalidone caused a significant increase in serum glucose and uric acid and a decrease in K+, whereas no change was observed during cadralazine It is concluded that cadralazine given once a day with atenolol has the same efficacy in controlling blood pressure at rest as the combination of atenolol and chlorthalidone, and in addition it improves the pressor response to dynamic exercise and does not cause unwanted metabolic effects.
Similar content being viewed by others
References
Semeraro C, Dorigotti L, Banfi C, Carpi C (1981) Pharmacological studies on cadralazine: A new antihypertensive vasodilator drug. J Cardiovasc Pharmacol 3: 455–467
Van Brummelen P, Bühler FR, Kiowsky W, Bolli P, Bertel O (1979) Antihypertensive efficacy of a new long acting vasodilator, ISF 2469, in combination with a beta-blocker and a diuretic. Int J Clin Pharmacol Biopharm 17: 380–385
Amann FW, Bühler FR (1979) Long-term antihypertensive therapy with a new vasodilator, ISF 2469 in combination with a beta-blocker and a diuretic. Clinica Europea 6: 1029–1034
Strocchi E, Costa FV, Malini PL, Marata AM, Parini J, Ambrosioni E (1983) Comparison of the antihypertensive activity of cadralazine (ISF 2469) and dihydralazine during chronic treatment. Int J Clin Pharmacol Ther Toxicol 21: 519–523
Catalano M, Parini J, Libretti A (1983) Cadralazine (ISF 2469) dose-related antihypertensive activity after single oral administration to patients. Eur J Clin Pharmacol 24: 157–161
Semplicini A, Pessina AC, Caregaro L, Gatta A, Samà B, Rossi GP, Dal Palù C (1983) Blood pressure, body fluids and renal tubular handling of sodium during cadralazine plus atenolol treatment in essential hypertension. Curr Ther Res 34: 1038–1043
Costa FV, Marata AM, Ambrosioni E (1983) Efficacy and tolerability of a long-acting vasodilator, cadralazine (ISF 2469), in hypertensive patients: results after one year of treatment. Curr Ther Res 34: 653–661
Catalano M, Parini J, Romano M, Libretti A (1985) Controlled clinical trial with cadralazine as a second-step drug in the treatment of hypertension. Eur J Clin Pharmacol 28: 135–138
Silas JH, Barker AT, Ramsay LE (1980) Clinical evaluation of Dinamap 845 automated blood pressure recorder. Br Heart J 43: 202–208
Amery A, Julius S, Whitlock LS, Conway J (1967) Influence of hypertension on the hemodynamic response to exercise. Circulation 36: 231–237
Ambrosioni E, Costa FV, Montebugnoli L, Bassein L, Marchesini B, Magnani B (1983) Comparison of the antihypertensive efficacy of atenolol, oxprenolol and pindolol at rest and during exercise. Drugs 25 [Suppl 2]: 30–36
Costa FV, Caldari R, Borghi C, Bassein L, Ambrosioni E (1984) Acebutolol, atenolol and nadolol: Comparison of their antihypertensive efficacy at rest and during exercise. Curr Ther Res 35: 961–973
Quinones J, Cardùs D (1983) Blood pressure response to submaximal exercise. In: Blocker WP Jr, Carrons D (eds) Rehabilitation in ischemic heart disease. MTP Press, Lancaster, pp 231–236
Folkow B, Hallbäck-Nordlander M, Lundgren Y, Sivertsson R, Weiss L (1982) The importance of adaptative design for the establishment and maintenance of primary hypertension as studied in man and in the spontaneously hypertensive rat. In: Okamoto K (ed) Spontaneous hypertension. Springer, Berlin Heidelberg New York, pp 103
Perez-Stable E, Caralis PV (1983) Thiazide-induced disturbances in carbohydrate, lipid and potassium metabolism. Am Heart J 106: 245–251
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Costa, F.V., Borghi, C., Mussi, A. et al. Cadralazine and chlorthalidone as a second-step drug with atenolol in hypertensive patients: Differences in blood pressure control during exercise. Eur J Clin Pharmacol 30, 145–150 (1986). https://doi.org/10.1007/BF00614292
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00614292